Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC-3S immunoprotective vaccine plus antiretroviral therapy in HIV-1 infection (Phase II)
2013-002735-23Phase 2Completed
- Sponsor
- InnaVirVax
- Start
- Sep 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VAC-3S in human immunodeficiency virus infection (HIV) (4 arms), sponsored by InnaVirVax. Primary endpoint: Change in anti-3S antibody titers. Started Sep 2013; status: completed.
02
Drugs
VAC-3S
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2013-002735-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002735-23.